Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 50,393 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Prostate Cancer
Interventions: pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment; Drug · Procedure
Lead sponsor: Imunon; Industry
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Shreveport, Louisiana • Myrtle Beach, South Carolina

Conditions: Hodgkin Lymphoma, Adult
Interventions: Brentuximab vedotin, ABVD; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 6
States / cities: Duarte, California • Rochester, Minnesota • Chapel Hill, North Carolina + 3 more

Conditions: Lymphedema, Malignant Neoplasm
Interventions: recombinant human hyaluronidase; Biological
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions: Th2 cells in allo HSCTT, Th2 Cells; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tobacco Use Cessation
Interventions: Questionnaire, Interview; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High-risk Prostate Cancer, Prostate Cancer
Interventions: HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Baltimore, Maryland

Conditions: Cervical Cancer, Cancer of the Cervix
Interventions: Transvaginal probe using photoacoustic and ultrasound imaging; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bladder Cancer
Interventions: Dovitinib; Drug
Lead sponsor: Noah Hahn, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Rockledge, Pennsylvania

Conditions: Central Nervous System Tumors
Interventions: BLZ-100; Drug
Lead sponsor: Blaze Bioscience Inc.; Industry
Eligibility: 1 Month to 30 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer
Interventions: Pemetrexed, Bevacizumab; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leukemia, Myeloid, Chronic
Interventions: Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Interventions: CEST-MRF; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: paclitaxel, antitumor drug screening assay; Drug · Other
Lead sponsor: Oncotech; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 9
States / cities: Fountain Valley, California • Long Beach, California • Los Angeles, California + 5 more

Conditions: Colon Cancer
Interventions: Exercise, Meditation; Behavioral
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions: Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Torrance, California • New Orleans, Louisiana • Annapolis, Maryland

Conditions: Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvocidib, pharmacological study, fludeoxyglucose F 18, fluorine F 18 fluorothymidine, positron emission tomography; Drug · Other · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,089 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 34
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more

Conditions: Rectal Cancer, Rectosigmoid Cancer
Interventions: Physical Activity, Survey, Telehealth Lifestyle Coaching; Other · Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer Adenocarcinoma in Situ
Interventions: degarelix acetate, Cyclophosphamide, GVAX; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 21 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate; Biological · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Endometrial Cancer
Interventions: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 62
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 30 more

Search by objective public record fields.

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Ultrasound and Photoacoustic Imaging for Cervical Cancer

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

Strength for Health

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Physical Activity in Rectal Cancer Survivors

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma